Levothyroxine Sodium (Levothyroxine Sodium) Patent Expiration, LOE Window & CMS Spending

Levothyroxine Sodium (Levothyroxine Sodium) by Fresenius Kabi: FDA Orange Book LOE 2032-10-03, 7 AB generics, $559.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN202231 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-10-03
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$559.9M
2024 Medicare Part D Spend$464.2M
2024 Medicaid Spend$95.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.